Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
Figure 2
Patient with partial response in lymph nodes but progression in bone. CT scans before (a) and after (b) 6 months of therapy with a TKI. The patient had a partial response in mediastinal and hilar adenopathy but progression in bone with cortical destruction. The patient’s bone lesions were irradiated, and he was restarted on the TKI. The patient continues on the TKI after 24 months and has no further evidence of progression.
